XGenomes
YC W19Boston, US · Founded 2017 · 6 employees · 4 known investors
XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.
Also known as XGenomes Corp.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesGenomicsUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (W19)
XGenomes was founded in 2017 by Kalim Mir.
KM
Kalim MirinFounder/CEO
Investors · 4
Competitors · 8
by search overlap10x Genomics 1-color7 shared keywords10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
IDbyDNA5 shared keywordsScalable, high throughput DNA sequencing platforms.
Nucleome5 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Myome5 shared keywordsMyOme uses whole genome sequencing and bioinformatics to analyze a single patient sample and produce clinically actionable reports, offering both proactive health tests (such as polygenic risk scores and medication response) and diagnostic tests for rare disease. Its genomic testing serves healthcare providers, patients, employers, and health systems to guide prevention, treatment, and lifestyle decisions.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
nChroma Bio4 shared keywordsnChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.
OneOme4 shared keywordsOneOme provides pharmacogenomic (PGx) products and services, centered on its RightMed Test that analyzes a patient's DNA to inform medication decisions. It serves health systems, payers, PBMs, employers, providers, and pharmacists with clinical consults, EHR integration, and population health tools.
Immunome3 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Companies competing with XGenomes for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $280K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does XGenomes do?
- XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.
- Who founded XGenomes?
- XGenomes was founded by Kalim Mir in 2017.
- Who are XGenomes's investors?
- XGenomes's investors include FundersClub, Y Combinator, FCVC, HOF Capital.
- Where is XGenomes headquartered?
- XGenomes is headquartered in Boston, US.